Targeting replication stress to improve treatment for small cell lung cancer
Official title: Investigating and Targeting Replication Stress in Small Cell Lung Cancer
Funded at New York University School of Medicine · NIH-11390982 · Data updated 2026-11-12
A large NIH grant is supporting research to understand why small cell lung cancer stops responding to chemotherapy and to find new ways to overcome resistance.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 16, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,893,978 |
| NIH project number | 5P01CA288368-03 |
| Project ID | NIH-11390982 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with small cell lung cancer, especially those with advanced or relapsed disease, could benefit from future therapies derived from this research.
✕Less likely to help
Patients whose cancer biology does not align with the studied pathways may not see direct benefits.
What this research studies
This project focuses on small cell lung cancer, a deadly form of lung cancer, and aims to uncover the biological reasons why it becomes resistant to standard treatments. Researchers will examine how SLFN11 and replication stress pathways affect chemo-sensitivity, using human cancer cell lines and model systems. The goal is to develop strategies that can make existing therapies work better and prevent relapse for patients with extensive-stage disease.
Why it matters
Potential benefit: If successful, the work could lead to new treatment approaches that make chemotherapy more effective and help patients with SCLC live longer.
How similar studies have gone: Previous research has shown that replication stress pathways influence chemo-sensitivity, but this project aims to translate those findings into targeted strategies for SCLC.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Huang, Tony Tung — New York University School of Medicine
- Study coordinator: Huang, Tony Tung
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.